IMV Inc.

At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. I must advise you that this conference is being recorded today, November 11th, 2021, and I would now like to hand the conference over to your first speaker, Joy Bessinger, Senior Vice President, Investor Relations and Corporate Strategy. Please go ahead.

Thank you, Operator. Good morning, all. I'm Joy Bessinger, Senior Vice President of Investor Relations and Corporate Strategy for IMB. And I'm pleased to welcome you to IMB's third quarter clinical and operational update conference call. I am joined today by Andrew Hall, our Interim CEO, Dr. Jeremy Graf, our Chief Scientific Officer, and last but certainly not least, Pira Labbe, our Chief Financial Officer. During this call, we will be discussing statements and our business outlook. Any forward-looking statements made today are pursuant to and within the meaning of the Safe Harbor provisions of applicable securities laws. These comments are based on current expectations of management regarding future events and operating performance and should not be seen as guarantees of future performance or results. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks are discussed in our continuous disclosure documents filed in compliance with applicable securities laws in Canada and the United States. The press release, the MD&A, and the financial statements have all been posted to our website at imv-inc.com. If you wish to receive a copy of these documents, please do not hesitate to contact us. Please note that we will be taking questions from sell-side analysts only today. And with that, I will now turn the call over to Andrew. Andrew?

Thank you, Joy. And welcome everyone to IMV's clinical, operational and third quarter results call. I will first provide an update on our corporate strategy. Jeremy will then discuss recent highlights of our clinical, translational and foundational programs, followed by Pierre, who will give a brief overview of our financial results before we take questions. IMV is undergoing a pivotal transition. we are realigning our corporate strategy to focus on IMV strengths and core competencies in immune oncology. First, and with the highest priority, we remain committed to accelerating Maverick PEPMA-S and DPX-MAGE towards registration by confirmation of their clinical benefits to patients. We also look to enhance the value of both products by exploring other therapeutic combinations beyond checkpoint inhibitors and indications supported by our ever increasing understanding of tumor biology. A second leg of our strategy is to leverage the versatility and unique mechanism of action of the DPX platform. The goal here is to develop a comprehensive portfolio of immune educating therapies that are improved by the combination when in formulation with DPX. We see this as a plug and play model in which we may in license a program, strengthen it, and then return it to the collaborator for further development. The third leg of our strategy is to enhance our technology platform to enable therapeutic combinations beyond peptides. Our recently announced collaboration with Medicago is an example of this. We're in collaboration. We will evaluate the combination of their VLP technology with our DPX platform to confirm enhancement of the therapeutic profile. This collaboration and others to be announced will confirm the value DPX creates when combined with VLPs, mRNAs, small molecules, and even protein therapeutics. The final part of our strategy is to actively monetize our non-immune oncology programs. So to focus IMV exclusively in oncology. This shift of focus will be supported by an increased foundational research effort and peer reviewed strategy led by Jeremy. In the coming months, we will continue showcasing our science at scientific congresses and through publication to demonstrate the robustness of our platform's mechanism of action, as well as the safety, efficacy, and importantly, durability of our clinical candidates. Building on the clinical data and transformational information we accrued this year, we are initiating trials that will take our lead compound forward towards registration. So with this clarity on strategy, we also strengthened our management team with two experienced industry professionals. Joey Bessinger, who introduced this call, joined IMV as Senior Vice President, Investor Relations and Corporate Strategy. And Dr. Heather Hirsch joined IMV as Vice President, Translational Research. Both Heather and Joey are US-based. Heather from our new office in Cambridge. Her background in translational analysis and her expertise at CRISPR, Johnson and Merck will certainly help our research and importantly business development footprint in the Boston area. We are pleased with our recent progress. We've enhanced the versatility of our DPX delivery technology and continued the validation of Mavarapipmin S in patients with advanced recurrent ovarian cancer and with relapsed and refractory DLVCL. I'll now pass the call over to Jeremy to dig a little deeper into the scientific progress we've made. So I'll pass it to you, Jeremy.